Composite versus individual biomarkers for predicting clinical benefit to PD-1 blockade in NSCLC 123 3 PPV NPV AUC AUC 95% CI lower limit AUC 95% CI upper limit 42 100 81 64 98 41 94 79 63 95 38 94 76 62 91 39 93 77 63 91 39 93 76 62 90 39 93 77 62 91 38 93 74 58 89 38 93 74 59 88 38 93 78 63 92 38 92 78 63 93 38 92 59 42 76 38 92 76 61 92 35 92 76 60 91 34 91 77 61 92 35 100 85 66 100 35 90 64 47 80 31 75 78 62 93 31 75 75 59 92 31 75 75 59 92 29 75 74 57 90 31 100 64 49 80 29 NA 54 36 72 30 NA 62 46 77 30 NA 60 44 76 30 NA 58 41 76
RkJQdWJsaXNoZXIy MTk4NDMw